Montbretin Clinical Trial in Healthy Volunteers and Type 2 Diabetics

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Type 2 Diabetes
Interventions
DIETARY_SUPPLEMENT

Montbretin A

The investigational product is 95% pure montbretin A (MbA), a glycosylated acyl-flavonol isolated from the corms (bulbs) of the Crocosmia plant through hot water extraction. It is a potent and specific inhibitor of human pancreatic amylase (HPA).

Trial Locations (1)

V5Y2S7

RECRUITING

VCHRI Clinical Research Unit, Vancouver

All Listed Sponsors
collaborator

Michael Smith Foundation for Health Research

OTHER

collaborator

Canadian Glycomics Network (GlycoNet) - Networks of Centres of Excellence (NCE)

UNKNOWN

lead

Robert Petrella

OTHER